Vinay Prasad

Person

Last mentioned: 2h ago

Timeline

  1. Industry Warning

    Editorials warn that erratic FDA behavior is a threat to biotech innovation.

  2. Refusal to File

    FDA regulator Vinay Prasad refuses to review Moderna's flu vaccine application.

  3. Regulatory Alignment

    FDA officials reportedly signal support for Moderna's trial data workaround.

  4. Grant Rescission

    The federal government rescinds hundreds of millions in mRNA research funding.

  5. Peak Valuation

    Moderna reaches a market capitalization of $200 billion during the pandemic height.

Stories mentioning Vinay Prasad 1

Financial Regulation Bearish

FDA Regulatory Shift Threatens Biotech Innovation and Moderna's Recovery

Moderna Inc. faces a critical juncture as the FDA's increasingly erratic regulatory stance and shifting White House sentiment jeopardize the future of mRNA technology. A rare refusal to review the company's flu vaccine data highlights a growing rift between the agency and the industry it oversees, threatening the predictability required for biotech investment.

2 sources